

(SEQ ID NO: 26)
5' -GCAACUCAUUGGACAUCAUUC-3'

(SEQ ID NO: 30)
3' -AUCGUUGAGUAACCUGUAGUA-5',

wherein the bolded and underlined nucleotides are 2'OMe nucleotides.

2. A nucleic acid-lipid particle comprising:
 - (a) a composition of claim 1;
 - (b) a cationic lipid; and
 - (c) a non-cationic lipid.
3. The nucleic acid-lipid particle of claim 2, wherein the particle further comprises a conjugated lipid that inhibits aggregation of particles.
4. A method for introducing an interfering RNA that silences Ebola virus gene expression into a cell, the method comprising:
 - contacting the cell with a nucleic acid-lipid particle of claim 2.
5. A method for silencing Ebola virus gene expression in a mammal in need thereof, the method comprising:
 - administering to the mammal a nucleic acid-lipid particle of claim 2.
6. A method for the in vivo delivery of a cocktail of interfering RNA that silences Ebola virus gene expression, the method comprising:
 - administering to a mammal a nucleic acid-lipid particle of claim 2.
7. A method for treating and/or ameliorating one or more symptoms associated with an Ebola virus infection in a mammal in need thereof, the method comprising:
 - administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle of claim 2.
8. A method for inactivating and/or inhibiting the replication of Ebola virus in a mammal in need thereof, the method comprising:
 - administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle of claim 2.
9. A method for preventing and/or treating hemorrhagic fever in a mammal in need thereof, the method comprising:
 - administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle of claim 2.
10. The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

11. The nucleic acid-lipid particle of claim 2, wherein the cationic lipid comprises 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-di- γ -linolenyloxy-N,N-dimethylaminopropane (γ -DLinDMA), 2,2-dilinoleyloxy-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-K-C2-DMA), 2,2-dilinoleyloxy-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-K-DMA), or a mixture thereof.

12. The nucleic acid-lipid particle of claim 2, wherein the non-cationic lipid is selected from the group consisting of a phospholipid, cholesterol, or a mixture of a phospholipid and cholesterol.

13. The nucleic acid-lipid particle of claim 12, wherein the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.

14. The nucleic acid-lipid particle of claim 12, wherein the cholesterol is a cholesterol derivative.

15. The nucleic acid-lipid particle of claim 3, wherein the conjugated lipid that inhibits aggregation of particles comprises a polyethyleneglycol (PEG)-lipid conjugate.

16. The nucleic acid-lipid particle of claim 15, wherein the PEG-lipid conjugate is member selected from the group consisting of a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof.

17. The nucleic acid-lipid particle of claim 16, wherein the PEG-lipid conjugate is a PEG-DAA conjugate.

18. The nucleic acid-lipid particle of claim 17, wherein the PEG-DAA conjugate is selected from the group consisting of a PEG-didecyloxypropyl (C₁₀) conjugate, a PEG-dilauryloxypropyl (C₁₂) conjugate, a PEG-dimyristyloxypropyl (C₁₄) conjugate, a PEG-dipalmitoyloxypropyl (C₁₆) conjugate, a PEG-distearoyloxypropyl (C₁₈) conjugate, and a mixture thereof.

19. The nucleic acid-lipid particle of claim 2, wherein the composition is fully encapsulated in the nucleic acid-lipid particle.

20. A pharmaceutical composition comprising a nucleic acid-lipid particle of claim 2 and a pharmaceutically acceptable carrier.

* * * * *